To conduct a head-to-head comparison of the clinical value of Al18F-NOTA-FAPI-04 PET/CT and 18F-FDG PET/CT in the diagnosis of gastric adenocarcinoma. Fourteen patients with gastric cancer who underwent diagnosis and treatment at the Affiliated Hospital of North Sichuan Medical College between July 2023 and January 2024 were prospectively enrolled. All patients underwent both imaging modalities within one week. The Wilcoxon signed-rank test or McNemar test was used to compare the standardized uptake value maximum (SUVmax), standardized uptake value mean (SUVmean), tumor-to-background ratio (TBR), and positive detection rates between the two methods. The positive detection rate of Al18F-NOTA-FAPI-04 PET/CT for primary gastric lesions or postoperative recurrences was 100
In the diagnostic workup of inflammatory, infective, and infiltrative cardiac diseases such as endocarditis or cardiac sarcoidosis, ¹⁸F-FDG PET/CT requires adequate suppression of physiological myocardial glucose uptake. Current international guidelines provide general dietary principles but fail to adequately address complex clinical scenarios encountered in the inpatient setting. We developed a structured operational algorithm through multidisciplinary collaboration between Nuclear Medicine, Clinical Dietetics and Diabetology specialists, presented as a single-page reference table combining three patient categories (non-diabetic, diabetic on oral therapy, insulin-dependent diabetic) with three nutritional modalities (oral, enteral, parenteral). For each combination, clear, time-referenced instructions are provided. The protocol was formally adopted and shared with all referring wards of our hospital through a dedicated educational program; these preliminary findings warrant formal prospective validation. The practical tool presented here addresses a concrete gap not covered by current international guidelines and may serve as a reference for other Nuclear Medicine centers facing similar challenges in the inpatient setting.
To systematically evaluate the diagnostic performance and therapeutic value of radiolabeled FAP-2286 in solid tumors. A systematic review and meta-analysis were conducted in accordance with the PRISMA guidelines. PubMed, Embase, Scopus, and Web of Science were searched from database inception to December 6, 2025. Clinical studies investigating radiolabeled FAP-2286 for tumor imaging or therapy were included. A random-effects model was used to pool standardized mean differences (SMDs) or proportional effect sizes. A total of 11 studies (7 diagnostic and 4 therapeutic) involving 378 patients (336 for diagnosis and 42 for therapy) were included. Diagnostic analysis showed that FAP-2286 PET demonstrated significantly higher uptake in primary tumors compared to 18F-FDG PET (SMD = 0.98, 95
To evaluate whether interim [¹⁸F]fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) Deauville 4–5 is associated with event-free survival (EFS) and late treatment-related toxicity in pediatric Hodgkin lymphoma, and to assess inter-reader reproducibility. This retrospective single-center cohort included 70 consecutive patients aged ≤ 18 years with newly diagnosed Hodgkin lymphoma treated during 2015–2025; interim PET/CT after two chemotherapy cycles was available for 59. Deauville scores were classified as 1–3 or 4–5. A second nuclear medicine physician re-evaluated the examinations, and agreement was quantified using Cohen’s kappa. EFS was analyzed using Kaplan–Meier and Cox methods. The three-covariate Cox model, based on only 11 events, was strictly exploratory and could not establish independent prognostic value. Late toxicity was defined as a new or persistent treatment-related condition documented ≥ 3 months after first-line therapy. During a median follow-up of 43.8 months, 12 patients in the full cohort of 70 experienced an EFS event; 11 of these patients belonged to the subgroup of 59 with available interim PET/CT. Among those with interim PET/CT, 50 had Deauville 1–3 and 9 had Deauville 4–5. Agreement was excellent (κ = 0.85). Deauville 4–5 was associated with inferior EFS (log-rank p < 0.001); the exploratory model adjusted for stage and bulky disease yielded a hazard ratio of 10.95 (95
To test whether baseline ¹⁸F-FDG PET radiomics adds value to routine clinical variables for predicting pathological complete response (pCR) in HER2-positive breast cancer, with internal validation. We studied 137 patients with HER2-positive breast cancer treated with neoadjuvant therapy. Eight clinical variables and 34 reproducible, non-redundant radiomic features formed a single candidate pool. Within every cross-validation fold, elastic-net penalized logistic regression was fitted to the whole pool, so that all candidates, including clinical variables, underwent the same penalized selection. Five models (Combined, Radiomics-only, Clinical-only, conventional PET, PET + Clinical) were compared by pooled 25 × 5 repeated cross-validation, and selection stability was recorded across folds. pCR occurred in 62/137 patients (45.3
